Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids

被引:53
作者
Chikh, GG
Li, WM
Schutze-Redelmeier, MP
Meunier, JC
Bally, MB
机构
[1] British Columbia Canc Res Ctr, Dept Adv Therapeut, Vancouver, BC V5Z 1L3, Canada
[2] Inst Natl Agron Paris Grignon, Chim Biol Lab, F-75005 Paris, France
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada
[4] Celator Technol Inc, Vancouver, BC V5Z 1G1, Canada
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 2002年 / 1567卷 / 1-2期
关键词
metal-ion-chelating lipid; liposome; peptide; poly-histidine tag; targeting; delivery;
D O I
10.1016/S0005-2736(02)00618-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The therapeutic potential of selected peptides and proteins is enormous, with applications ranging from use as therapeutic vaccines, as modulators of intracellular signaling pathways and as highly selective agents capable of recognizing unique extracellular targets. We have been pursuing development of hybrid lipid-based carrier formulations designed to take advantage of the therapeutic benefits of peptides selected for their ability to act in a complementary fashion with the carrier system. In this regard, it is critical to have simple and versatile methods to promote and control the binding of diverse peptides to a broad range of carrier formulations. As demonstrated here, recombinant proteins and synthetic peptides containing poly-histidine residues (4 to 10) can be specifically bound to liposomes containing a metal-ion-chelating lipid, DOGS-NTA-Ni. The potential of this approach is demonstrated using two functional peptides, AntpHD-Cw3 (applications for vaccine production) and AHNP (specificity for Her-2 expressing cells). (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 30 条
[1]   Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity [J].
Adlakha-Hutcheon, G ;
Bally, MB ;
Shew, CR ;
Madden, TD .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :775-779
[2]  
Bally MM, 1993, LIPOSOME TECHNOLOGY, P27
[3]   Immunoliposomes - A promising approach to targeting cancer therapy [J].
Bendas, G .
BIODRUGS, 2001, 15 (04) :215-224
[4]  
Buzard Gregory S., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P179
[5]   Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes [J].
Chikh, G ;
Bally, M ;
Schutze-Redelmeier, MP .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 254 (1-2) :119-135
[6]   Efficient delivery of antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells [J].
Chikh, GG ;
Kong, S ;
Bally, MB ;
Meunier, JC ;
Schutze-Redelmeier, MPM .
JOURNAL OF IMMUNOLOGY, 2001, 167 (11) :6462-6470
[7]   Monoclonal antibody therapy for lymphoma -: An update [J].
Dillman, RO .
CANCER PRACTICE, 2001, 9 (02) :71-80
[8]   Orientation and two-dimensional organization of proteins at chelator lipid interfaces [J].
Dorn, IT ;
Pawlitschko, K ;
Pettinger, SC ;
Tampe, R .
BIOLOGICAL CHEMISTRY, 1998, 379 (8-9) :1151-1159
[9]   MHC-DEPENDENT ANTIGEN-PROCESSING AND PEPTIDE PRESENTATION - PROVIDING LIGANDS FOR T-LYMPHOCYTE ACTIVATION [J].
GERMAIN, RN .
CELL, 1994, 76 (02) :287-299
[10]   Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses [J].
Guan, HH ;
Budzynski, W ;
Koganty, RR ;
Krantz, MJ ;
Reddish, MA ;
Rogers, JA ;
Longenecker, BM ;
Samuel, J .
BIOCONJUGATE CHEMISTRY, 1998, 9 (04) :451-458